PRESS RELEASE published on 05/20/2026 at 20:45, 4 months 17 days ago Inside Information / Other news releases MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF published on 04/21/2026 at 15:14, 5 months 16 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 5 months 16 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 6 months 6 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 6 months 6 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 6 months 6 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 6 months 7 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 8 months 17 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
PRESS RELEASE published on 01/20/2026 at 18:30, 8 months 17 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 9 months 28 days ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
Published on 10/07/2026 at 17:00, 34 minutes ago BlackBerry Radar Expands Asset Intelligence Platform with Dynamic Pairing
Published on 10/07/2026 at 15:30, 2 hours 4 minutes ago Gold Port Announces Marketing Agreement with NAI Interactive Ltd.
Published on 10/07/2026 at 14:30, 3 hours 4 minutes ago Secure Blockchain's Agentic Solutions Signs Financial Services Firm, Expanding Enterprise AI Into Corporate Finance
Published on 10/07/2026 at 13:33, 4 hours 1 minute ago BULGOLD Samples 21.2g/t Gold at Surface and Expands Kopernica Footprint by 170% to 1,700 Metres by 800 Metres, Lutila Project
Published on 10/07/2026 at 13:00, 4 hours 34 minutes ago ATHA Energy Successfully Completes Diamond Drilling at RIB North Discovery, Expanding Strike Length To 3.4 Km, And Identifies a Higher-Grade Sub Zone: Results Include RIBN-DD-023 Intersecting 19.5 M Of Composite Uranium Mineralization With 2.0 M Of High-G
Published on 10/07/2026 at 16:54, 39 minutes ago EQS-Adhoc: Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza
Published on 10/07/2026 at 16:09, 1 hour 24 minutes ago EQS-Adhoc: AMAG Austria Metall AG: Increase of EBITDA Guidance for Fiscal Year 2026
Published on 10/07/2026 at 15:45, 1 hour 48 minutes ago EQS-Adhoc: VINCORION SE: VINCORION SE reports 41% higher revenue for the first 9 months of 2026 compared to the same period last year; Full-Year Guidance raised
Published on 10/07/2026 at 14:58, 2 hours 35 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 10/07/2026 at 15:54, 1 hour 40 minutes ago Disclosure of Share Capital and Voting Rights as of September 30, 2026
Published on 10/07/2026 at 08:15, 9 hours 19 minutes ago EURAZEO TO ACQUIRE MIYA WATER, A GLOBAL SPECIALIST IN EFFICIENT WATER MANAGEMENT SOLUTIONS
Published on 10/07/2026 at 08:00, 9 hours 34 minutes ago Neoen launches construction of its 346 MW Goyder North Wind Farm in South Australia
Published on 10/06/2026 at 19:15, 22 hours 19 minutes ago Air Liquide has successfully issued a 2 billion euros multi-tranche bond
Published on 10/06/2026 at 18:39, 22 hours 54 minutes ago Total number of voting rights and shares making up the share capital at September 30, 2026
